Literature DB >> 6298277

2-Methylthioadenosine[beta-32P]diphosphate. An agonist and radioligand for the receptor that inhibits the accumulation of cyclic AMP in intact blood platelets.

D E Macfarlane, P C Srivastava, D C Mills.   

Abstract

2-Methylthio-ADP and its radioactive analogue [beta-32P]2-methylthio-ADP were synthesized and used to investigate platelet receptors for ADP. 2-Methylthio-ADP induced platelet aggregation and shape change, and inhibited cyclic AMP accumulation in platelets exposed to prostaglandin E1. Compared with ADP, 2-methylthio-ADP was 3-5 times as active as an aggregating agent and 150-200 times as active as an inhibitor of cyclic AMP accumulation. Binding of [beta-32P]2-methylthio-ADP to platelets was measured after centrifuging them through silicone oil to separate platelets from their suspension medium. Binding was reversible, saturable, and specific, with between 400 and 1,200 sites/cell in different platelet preparations. There was no evidence for a second class of binding sites with different affinity. The second order association rate constant was approximately 3.5 X 10(6) M-1 S-1, and the first order dissociation rate was 0.024 s-1, both measured at 23 degrees C. The dissociation equilibrium constant (approximately 15 nM) was about three times higher than the concentration giving half-maximal inhibition of prostaglandin E1-stimulated cyclic AMP accumulation in platelet-rich plasma. Binding was inhibited by ADP (Ki = 3.5 microM), ATP (7 microM), 2-azido-ADP (0.12 microM), inosine diphosphate (IDP, 150 microM), guanosine diphosphate (GDP, 350 microM), and AMP (800 microM). Binding of 2-methylthio-ADP was also blocked by the non-cell-penetrating thiol reagent, p-mercuribenzene sulphonate, a reagent that blocks the inhibition of adenylate cyclase by ADP, but which does not block the ability of ADP to induce aggregation or platelet shape change. The amount of 2-methylthio-ADP bound at saturation was independent of pH in the range 6-8, but the affinity was reduced at pH 6 compared with pH 6.5-8.0. The dissociation constant was not temperature dependent in the range 32 degrees -40 degrees C, whereas the rate of dissociation of 2-methylthio-ADP from platelets after the addition of an excess of ADP approximately doubled over this range. The activation energy for dissociation was approximately 15 kcal/mol. Our results support the conclusion that platelets have a receptor for ADP, which inhibits cyclic AMP accumulation, and which has a sulphydryl group in the binding pocket.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6298277      PMCID: PMC436889          DOI: 10.1172/jci110786

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  11 in total

1.  Enzyme activities on the platelet surface in relation to the action of adenosine diphosphate.

Authors:  J F Mustard; M A Packham; D W Perry; M A Guccione; R L Kinlough-Rathbone
Journal:  Ciba Found Symp       Date:  1975

2.  The effects of ATP on platelets: evidence against the central role of released ADP in primary aggregation.

Authors:  D E Macfarlane; D C Mills
Journal:  Blood       Date:  1975-09       Impact factor: 22.113

3.  Metabolism and function of human platelets washed by albumin density gradient separation.

Authors:  P N Walsh; D C Mills; J G White
Journal:  Br J Haematol       Date:  1977-06       Impact factor: 6.998

4.  Analogues of adenosine 5'-diphosphate-new platelet aggregators. Influence of purine ring and and phosphate chain substitutions on the platelet-aggregating potency of adenosine 5'-diphosphate.

Authors:  G Gough; M H Maguire; F Penglis
Journal:  Mol Pharmacol       Date:  1972-03       Impact factor: 4.436

5.  Use of [methyl-3H]Yohimbine as a radioligand for alpha-2 adrenoreceptors on intact platelets. Comparison with dihydroergocryptine.

Authors:  D E Macfarlane; B L Wright; D C Stump
Journal:  Thromb Res       Date:  1981 Oct 1-15       Impact factor: 3.944

6.  Binding of 2-azidoadenosine [beta-32P]diphosphate to the receptor on intact human blood platelets which inhibits adenylate cyclase.

Authors:  D E Macfarlane; D C Mills; P C Srivastava
Journal:  Biochemistry       Date:  1982-02-02       Impact factor: 3.162

7.  ADP is a potent inhibitor of human platelet plasma membrane adenylate cyclase.

Authors:  D M Cooper; M Rodbell
Journal:  Nature       Date:  1979-11-29       Impact factor: 49.962

8.  Parallel observation of the occupancy of the alpha 2-adrenergic receptor in intact platelets and its ability to inhibit the adenylate cyclase.

Authors:  D E Macfarlane; D C Stump
Journal:  Mol Pharmacol       Date:  1982-11       Impact factor: 4.436

9.  Binding of adenosine diphosphate to intact human platelets.

Authors:  G V Born; H Feinberg
Journal:  J Physiol       Date:  1975-10       Impact factor: 5.182

10.  Inhibition by ADP of prostaglandin induced accumulation of cyclic AMP in intact human platelets.

Authors:  D E Macfarlane; D C Mills
Journal:  J Cyclic Nucleotide Res       Date:  1981
View more
  15 in total

1.  Effects of the P2-purinoceptor antagonist, suramin, on human platelet aggregation induced by adenosine 5'-diphosphate.

Authors:  S M Hourani; D A Hall; C J Nieman
Journal:  Br J Pharmacol       Date:  1992-02       Impact factor: 8.739

2.  Historical perspective on ADP-induced platelet activation.

Authors:  Marian A Packham; Margaret L Rand
Journal:  Purinergic Signal       Date:  2011-04-02       Impact factor: 3.765

Review 3.  Extracellular ATP: effects, sources and fate.

Authors:  J L Gordon
Journal:  Biochem J       Date:  1986-01-15       Impact factor: 3.857

4.  Exogenous ATP and other nucleoside phosphates modulate epidermal growth factor receptors of A-431 epidermoid carcinoma cells.

Authors:  K Hosoi; M Edidin
Journal:  Proc Natl Acad Sci U S A       Date:  1989-06       Impact factor: 11.205

Review 5.  Nomenclature and classification of purinoceptors.

Authors:  B B Fredholm; M P Abbracchio; G Burnstock; J W Daly; T K Harden; K A Jacobson; P Leff; M Williams
Journal:  Pharmacol Rev       Date:  1994-06       Impact factor: 25.468

Review 6.  Identification, characterization, and inhibition of the platelet ADP receptors.

Authors:  C Gachet
Journal:  Int J Hematol       Date:  2001-12       Impact factor: 2.490

7.  The platelet P2Y(12) receptor under normal and pathological conditions. Assessment with the radiolabeled selective antagonist [(3)H]PSB-0413.

Authors:  Philippe Ohlmann; Anna Lecchi; Ali El-Tayeb; Christa E Müller; Marco Cattaneo; Christian Gachet
Journal:  Purinergic Signal       Date:  2012-08-15       Impact factor: 3.765

8.  Pharmacological characterization of the P2 receptors profile in the podocytes of the freshly isolated rat glomeruli.

Authors:  Daria V Ilatovskaya; Oleg Palygin; Vladislav Levchenko; Alexander Staruschenko
Journal:  Am J Physiol Cell Physiol       Date:  2013-09-18       Impact factor: 4.249

9.  An inherited bleeding disorder linked to a defective interaction between ADP and its receptor on platelets. Its influence on glycoprotein IIb-IIIa complex function.

Authors:  P Nurden; P Savi; E Heilmann; C Bihour; J M Herbert; J P Maffrand; A Nurden
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

10.  Effects of analogues of adenine nucleotides on increases in intracellular calcium mediated by P2T-purinoceptors on human blood platelets.

Authors:  D A Hall; S M Hourani
Journal:  Br J Pharmacol       Date:  1993-03       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.